OnKure Therapeutics (OKUR) Profit After Tax (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Profit After Tax data on file, last reported at -$15.2 million in Q1 2026.

• Quarterly Profit After Tax rose 4.82% year-over-year to -$15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.7 million (up 0.53% YoY) and the FY2025 annual result came in at -$59.5 million, down 12.99% from the prior year.
• Profit After Tax eased to -$15.2 million in Q1 2026, from -$13.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $18.5 million in Q4 2023 to a low of -$19.5 million in Q2 2023.
• A 5-year average of -$12.6 million and a median of -$14.1 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 236.8% — and 2024, when it slumped 194.16%.
• Tracing OKUR's Profit After Tax over 5 years: stood at -$13.5 million in 2022, then jumped by 236.8% to $18.5 million in 2023, then tumbled by 194.16% to -$17.4 million in 2024, then gained by 22.58% to -$13.5 million in 2025, then slipped by 12.25% to -$15.2 million in 2026.
• The last three Profit After Tax figures came in at -$15.2 million (Q1 2026), -$13.5 million (Q4 2025), and -$14.7 million (Q3 2025), per Business Quant data.